Despite the overwhelming success of vaccines in preventing infectious diseases, there remain numerous globally devastating diseases without fully protective vaccines, particularly …
MS Datoo, MH Natama, A Somé, O Traoré, T Rouamba… - The Lancet, 2021 - thelancet.com
Background Stalled progress in controlling Plasmodium falciparum malaria highlights the need for an effective and deployable vaccine. RTS, S/AS01, the most effective malaria …
Executive summary 50 years after a noble but flawed attempt to eradicate malaria in the mid- 20th century, the global malaria community is once again seriously considering eradication …
PE Duffy, J Patrick Gorres - npj Vaccines, 2020 - nature.com
Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …
Background The efficacy and safety of the RTS, S/AS01 candidate malaria vaccine during 18 months of follow-up have been published previously. Herein, we report the final results …
AM Didierlaurent, B Laupèze, A Di Pasquale… - Expert review of …, 2017 - Taylor & Francis
Introduction: Adjuvants are used to improve vaccine immunogenicity and efficacy by enhancing antigen presentation to antigen-specific immune cells with the aim to confer long …
A Mwakingwe-Omari, SA Healy, J Lane, DM Cook… - Nature, 2021 - nature.com
The global decline in malaria has stalled, emphasizing the need for vaccines that induce durable sterilizing immunity. Here we optimized regimens for chemoprophylaxis vaccination …
Background Development of an effective vaccine against the pathogenic blood-stage infection of human malaria has proved challenging, and no candidate vaccine has affected …
In recent years, various intervention strategies have reduced malaria morbidity and mortality, but further improvements probably depend upon development of a broadly protective …